Literature DB >> 18258343

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.

Pascal Mettens1, Patrice M Dubois, Marie-Ange Demoitié, Babak Bayat, Marie-Noëlle Donner, Patricia Bourguignon, V Ann Stewart, D Gray Heppner, Nathalie Garçon, Joe Cohen.   

Abstract

Protection against Plasmodium falciparum sporozoite infection can be achieved by vaccination with the recombinant circumsporozoite protein-based vaccine RTS,S formulated with the AS02A Adjuvant System. Since this protection is only partial and wanes over time, we have developed a new RTS,S-based vaccine adjuvanted with AS01B. RTS,S/AS01B-induced high specific antibody titers and increased the frequency of mouse CD4(+) and CD8(+) T cells expressing IFN-gamma, and of monkey CD4(+) T cells expressing IL-2 and/or IFN-gamma and/or TNF-alpha upon stimulation with vaccine antigens. Our data provides clear evidence that combining RTS,S antigen with a potent adjuvant induces strong humoral and cellular responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258343     DOI: 10.1016/j.vaccine.2007.12.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

Review 1.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

2.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

3.  Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(gamma-glutamic acid) nanoparticles.

Authors:  Takayuki Hamasaki; Tomofumi Uto; Takami Akagi; Mitsuru Akashi; Masanori Baba
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

4.  Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Authors:  Kathrin Kastenmüller; Diego A Espinosa; Lauren Trager; Cristina Stoyanov; Andres M Salazar; Santosh Pokalwar; Sanjay Singh; Sheetij Dutta; Christian F Ockenhouse; Fidel Zavala; Robert A Seder
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

5.  Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.

Authors:  Aneesh Vijayan; Carmen E Gómez; Diego A Espinosa; Alan G Goodman; Lucas Sanchez-Sampedro; Carlos Oscar S Sorzano; Fidel Zavala; Mariano Esteban
Journal:  J Immunol       Date:  2012-05-21       Impact factor: 5.422

6.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.

Authors:  Rhea N Coler; Ajay Bhatia; Jean-Francois Maisonneuve; Peter Probst; Brenda Barth; Pamela Ovendale; Hang Fang; Mark Alderson; Yves Lobet; Joe Cohen; Pascal Mettens; Steven G Reed
Journal:  FEMS Immunol Med Microbiol       Date:  2009-03

8.  Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA.

Authors:  B Ferraro; K T Talbott; A Balakrishnan; N Cisper; M P Morrow; N A Hutnick; D J Myles; D J Shedlock; N Obeng-Adjei; J Yan; A K K Kayatani; N Richie; W Cabrera; R Shiver; A S Khan; A S Brown; M Yang; U Wille-Reece; A J Birkett; N Y Sardesai; D B Weiner
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

9.  Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.

Authors:  John N Waitumbi; Samuel B Anyona; Carol W Hunja; Carolyne M Kifude; Mark E Polhemus; Douglas S Walsh; Chris F Ockenhouse; D Gray Heppner; Amanda Leach; Marc Lievens; W Ripley Ballou; Joe D Cohen; Colin J Sutherland
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

10.  Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Authors:  Mark E Polhemus; Shon A Remich; Bernhards R Ogutu; John N Waitumbi; Lucas Otieno; Stella Apollo; James F Cummings; Kent E Kester; Christian F Ockenhouse; Ann Stewart; Opokua Ofori-Anyinam; Isabelle Ramboer; Conor P Cahill; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Amanda Leach; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.